Dysregulation of cell metabolism and redox balance is implicated in the pathogenesis and progression of cancer and autoimmune diseases. Because the cell proliferation and apoptotic regulatory pathways are interconnected with metabolic and redox signalling pathways, the current mono-target treatment is ineffective, and multi-drug resistance remains common. Complex diseases are often implicated in a network-based context of pathology; therefore, a new holistic intervention approach is required to block multi-crosstalk in such complicated circumstances. The use of therapeutic agents isolated from herbs to holistically modulate metabolism and redox state has been shown to relieve carcinoma growth and the inflammatory response in autoimmune disorders. Multiple clinically applied or novel herbal chemicals with metabolic and redox modulatory capacity as well as low toxicity have recently been identified. Moreover, new metabolic targets and mechanisms of drug action have been discovered, leading to the exploration of new pathways for drug repositioning, clinical biomarker spectra, clinical treatment strategies and drug development. Taken together with multiple supporting examples, the modulation of cell metabolism and the redox capacity using herbal chemicals is emerging as a new, alternative strategy for the holistic treatment of cancer and autoimmune disorders. In the future, the development of new diagnostic tools based on the detection of metabolic and redox biomarkers, reformulation of optimized herbal compositions using artificial intelligence, and the combination of herbs with mono-targeting drugs will reveal new potential for clinical application.
Introduction
Increasing evidence suggests that dysregulation of metabolism and redox balance is implicated in the pathogenesis and progression of most cancers and autoimmune diseases (Deberardinis & Thompson, 2012; Watson, 2014) . Due to the crosstalk and interconnection between cell proliferation and the apoptotic and metabolic regulatory pathways, current mono-target-based therapies are unsatisfactory (Kaiser, 2011; Sams-Dodd, 2005) . These systemic diseases often share common pathological metabolic and redox characteristics (Leung, Cao, Jiang, Zhou, & Liu, 2013) , which implies that different diseases could be effectively treated with common methods and drugs, thus encouraging the pharmaceutical industry to focus on multi-targeted drug development and drug-repositioning (Dixon, & Stockwell, 2010; Leung et al., 2016; . In addition to the well-known classic Warburg effect (Ward & Thompson, 2012) , the recent ground-breaking Nobel Prize discovery regarding the importance of the circadian clock in regulating hormonal control and metabolism indicates a direct association of metabolism and health (Emery, So, Kaneko, Hall, & Rosbash, 1998; Gekakis et al., 1995) . Additionally, an increasing understanding of the role of cross-organ control, such as the lung-gut axis and brain-gut axis, in regulating multi-organ diseases (Masri et al., 2016; Wen, & Wong, 2017; Yang, & Zubcevic, 2017) and the recent evidence of lung cancer-induced resetting of liver metabolism (Masri et al., 2016) suggest that cell metabolism plays a non-neglectable role in the initiation and progression of complex disease. Large amounts of reactive oxygen species (ROS) are often generated during glucose metabolism, inducing oxidative stresses (Gorrini, Harris, & Mak, 2013) , leading to the viewpoint that the ROS need to be eliminated, and anti-oxidation was consequently proposed as an approach for treating multiple cancers and inflammatory diseases (Anastasiou et al., 2011; Schieber & Chandel, 2013) . However, this approach is controversial, due to the argument that antioxidants such as vitamin C do not prevent cancer and might potentially cause cancer (Watson, 2014) , suggesting that anti-oxidation alone might not be universally beneficial but is critical maintaining an optimal metabolic level and redox state in cells.
Clinically, complex diseases are difficult to treat with monotargeting drugs and require new holistic methods focusing on the metabolism and redox state of the whole body, possibly leading to a new approach in drug development. At the molecular level, the cellular microenvironment primarily involves metabolism (catabolism and anabolism (Hanahan & Weinberg, 2011) ) and redox reactions (oxidation and reduction (Gorrini et al., 2013) ), which are reversible, to maintain balance (Birsoy, Sabatini, & Possemato, 2012) . Autophagy is a normal physiological process regulating the rates of catabolism and anabolism and the AMP/ATP ratio under nutritional stimulation and controls the life or death fate of cells (Fujii, Khawaja, Dinardo, Atkins, & Janku, 2016; Guo & White, 2013) . However, the microenvironment of pathogenic cells is often different from that of normal cells, often exhibiting imbalances in metabolism and the redox state, favouring the generation of biomass, abnormal rates of autophagy and uncontrollable cell growth, resulting in the initiation of complex diseases such as cancer, rheumatoid arthritis (RA), systemic lupus erythaematosus (SLE) and type I diabetes (Ward & Thompson, 2012) . Thus, an increasing number of clinical trials on metabolic intervention drugs for these complex diseases are currently being conducted (Dowling, Zakikhani, Fantus, Pollak, & Sonenberg, 2007; Hirsch, Iliopoulos, & Struhl, 2013) ; one of the most typical examples is the mitochondrial metabolism inhibitor metformin (Dowling et al., 2007) , which is an FDA-approved anti-diabetics drug that is now undergoing clinical trials for repositioning as an anti-cancer drug (Hirsch et al., 2013) . Metformin and another well-characterized mitochondrial metabolism inhibitor, 2-deoxy-D-glucose (2-DG), can significantly reduce interferon-g production in SLE patients by normalizing T cell metabolism via inhibition of T cell glycolysis and mitochondrial metabolism (Yin et al., 2015) . Vitamin K3 can normalize the production of ROS and thereby effectively inhibit RA synovial inflammation, thus reversing RA . Therefore, the use of metabolic and redox interventions is a promising strategy for treating cancer and autoimmune conditions, and additional relevant drugs are expected to be developed from different sources, methods and technologies.
In the historical development and practice of traditional Chinese medicine (TCM), many effective herbs and formulations thereof have been well-documented. In particular, some herbal remedies function to adjust or modulate body metabolism and fluids, resulting in the reduction of blood glucose and lipids to treat multiple diseases (Kong et al., 2004) , which may provide clues for metabolic drug discovery or even drug repositioning. Herbs contain naturally existing chemicals with redox residues in their chemical structure (Dorrestein & Carroll, 2011) . For example, artemisinin is an herbal component of great interest that acts to treat malaria, the discovery of which was awarded the Nobel Prize (Shen, 2015) . It is now known that artemisinin not only cures malaria but also can be used to treat cancer and autoimmune conditions via modulating metabolism (Krishna, Bustamante, Haynes, & Staines, 2008; Su et al., 2016) . Berberine (BBR) is an herbal chemical undergoing phase I clinical trials in China for the treatment of diabetes, via reducing glucose and lipid metabolism, with treatment mechanism that is distinct from statins (Kong et al., 2004; Yin, Xing, & Ye, 2008; Zhang et al., 2010) and has been proven to have a therapeutic effect on cancer and RA in animals, via suppressing lipogenesis (Fan et al., 2018) . Considering these encouraging findings, the use of herbal medicines to treat complicated diseases by holistically modulating cancer metabolism and the redox state represents a new research arena that may connect TCM with conventional medicine, which should also be promoted to translating the power of TCM with new concepts, idea and techniques (Liu & Chen, 2011; Zhou & Chen, 2014) .
In this review, we have conducted a comprehensive analysis of reported findings regarding herbal chemicals that are effective in modulating cell metabolism and redox capacity. Together with our previously published data, we hope to elucidate the principles and mechanistic foundations of these chemicals. Additionally, we expect this review to help initiate intensive retrospective and perspective discussion among basic researchers, clinicians and the pharmaceutical industry, especially concerning the types of functional herbs and their components to be further investigated in detail as well as the procedures used for their investigation as new therapeutics, based on their metabolism and redox modulation characteristics.
Targeting cell metabolism to suppress cancer and autoimmune conditions
Cancer and autoimmune diseases are pathological conditions arising from abnormal cell proliferation and metabolic adaption of host immunity, resulting in uncontrollable cell growth and inflammation (Yang, Matteson, Goronzy, & Weyand, 2015) . Although these abnormal metabolic alterations are difficult to treat, they are targetable. Increasing evidence suggests that overexpression of the tryptophan-catabolizing enzyme IDO is associated with the progression of cancer and autoimmune diseases. By consuming tryptophan, IDO reduces the function of effector T cells and increases autoantibody titres generated by B cells (Scott et al., 2009; Smith et al., 2012) , relieving inflammation. Currently, five IDO inhibitors are being evaluated in clinical trials. Among these inhibitors, epacadostat, developed by Incyte, has undergone phase I/II clinical trials for combined use with immune checkpoint blockade (anti-PD-1 Ab), achieving promising T cell re-stimulation (Miao et al., 2017) . Similarly, multiple approaches have recently been evaluated for the targeting of other metabolic alterations, chiefly classified as biosynthetic pathway inhibitors and bioenergetic pathway modulators.
Biosynthetic pathway inhibitors
Nutrient competition is the most prominent feature of the microenvironment of highly proliferative cells. To facilitate self-survival and proliferation, cancerous and inflammatory cells rewire the metabolism to meet their increased demand for macromolecule biosynthesis (including nucleotides, lipids and proteins) to sustain their high proliferation rate (Yang et al., 2015) .
For nucleotide synthesis, cancerous and highly proliferative cells prefer anabolic glucose metabolism, while they switch to the pentose phosphate pathway (PPP) for the biosynthesis of ribose-5-phosphate and production of nicotinamide adenine dinucleotide phosphate (NADPH). Ribose-5-phosphate, a precursor for DNA synthesis, and NADPH, which is an anti-oxidant in the anabolic process, are critical for cell survival (Patra & Hay, 2014) . In addition, several tumour suppressors, including P53 and PTEN, suppress PPP (Jiang, Du, & Wu, 2014) , indicating suppression of the PPP flux as a promising therapeutic strategy. Targeting of the rate-limiting enzyme of PPP, glucose-6-phosphate dehydrogenase (G6PD), is currently undergoing clinical evaluation for cancer treatment. For instance, 6-amino-nicotinamide (6-AN) shows anti-cancer effects in numerous types of cancer via inhibiting G6PD with LD 50 : 40 mg/kg by oral administration in mice (Jiang et al., 2014; Rey et al., 2016) .
Cancerous and stimulated inflammatory cells also transfer excessive amounts of the glycolytic end product pyruvate to synthesize lipids, providing both energy and precursors for cell membrane formation and protein post-translational modification (Menendez & Lupu, 2007) . Sterol regulatory element-binding protein (SREBP), which is a critical transcription factor in lipid metabolism, is closely associated with cancer progression and poor survival as well as innate immune responses Im et al., 2011) . Therefore, similar to anabolic glucose metabolism, targeting lipogenesis is useful for combating highly proliferative diseases. SREBP, the master lipid regulator, controls the expression of a set of genes favouring lipogenesis and cell division, such as fatty acid synthase (FASN), HMG-COA reductase (HMGCR) and stearoyl-CoA desaturase-1 (SCD1) (Shimano & Sato, 2017) . In addition to its critical role in the de novo synthesis of lipids, SREBP is the upstream regulator of G6PD and PPP and thus plays an indirect role in regulating the proliferative capacity of cancer and T cells (Du et al., 2013) .
In multiple pre-clinical studies, lipid metabolism has been targeted for the treatment of cancer and autoimmune diseases, initiating a new round of drug repositioning. For example, metformin, an FDA-approved anti-diabetes drug, shows efficacy in cancer prevention by targeting the AMP-activated protein kinase (AMPK)-SREBP1 pathway (Sakoda et al., 2015; Yang, 2011) In the realm of herbal drug discovery, Kong et al. published a ground-breaking paper in Nature Medicine in 2004, reporting the cholesterol-lowering function of BBR via upregulating low-density lipoprotein receptor (LDLR) expression, exhibiting a different treatment mechanism from statins (Kong et al., 2004) . BBR lowers the cholesterol by elevating liver low-density lipoprotein receptor (LDLR) expression. The main function of LDLR is clearance of plasma LDL cholesterol (LDL-c) through receptor-mediated endocytosis. On the other hand, Statins inhibit the rate-limiting enzyme (HMG-CoA reductase) in cholesterol biosynthesis. BBR shows good safety (no LD 50 was found in the oral administrated mice at maximum dosage) and has been marketed in China for quite some time (Jahnke, Price, Marr, Myers, & George, 2006) . However, we recently observed that BBR displays versatile therapeutic functions in gefitinib-resistant lung cancer and RA models. Moreover, BBR results in better outcomes in the protection of bones from destruction than the clinically applied chemical drug methotrexate (MTX), via suppression of the AMPK-SREBP1 lipogenesis pathway published in Antioxidants and Redox Signalling in the cover page (Fan et al., 2018) . Additional lipid-modulating natural products such as catechins, linoleic acid and glabridin are currently being investigated in preclinical studies (Lee, Li, Li, & Li, 2011; Tokimitsu, 2004) .
In addition to lipogenesis, the mammalian target of rapamycin (mTOR) is a key integrative point for metabolic and growth signals. mTOR can be stimulated by nutrient availability and growth signalling pathways such as the phosphoinositide 3-kinase (PI3K) and AMPK pathways (Guertin & Sabatini, 2007) . In carcinogenesis, mTOR is frequently activated to stimulate cellular protein synthesis and cell growth by directly promoting ribosome biogenesis and the translation of numerous genes. Consequently, several mTOR inhibitors have been used in clinical settings, and additional natural products are undergoing preclinical studies, such as TMS, resveratrol and β-elemene (Fan et al., 2015; Liu et al., 2010; . Resveratrol has already been widely used as a dietary supplement, with an oral LD 50 N 800 mg/kg (Chen, Liu, Wang, & Liu, 2017) , and may be repositioned as a remedy for treating cancer.
Bioenergetic pathway modulators
As a critical master sensor of the cellular energy state, AMPK acts as a metabolic checkpoint to control cellular energy availability and biomass production. Null mutation of AMPK or AMPK inactivation is frequently observed in several types of cancers (Faubert, Vincent, Poffenberger, & Jones, 2015) . Salicylate, the metabolite of the pain killer aspirin, was recently proven to act as a direct activator of AMPK through inhibiting the dephosphorylation of Thr 172 (Hawley et al., 2012) . Subsequently, additional herbal AMPK activators such as BBR, thalidezine and hemandezine were reported (Fan et al., 2018; Law et al., 2016; Law et al., 2017) . In addition to direct activation of this master energy switch, there are two other bioenergetic pathways associated with metabolic shifts: glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle. For the former, Nobel Laureate Otto Warburg first observed the fundamental difference in metabolic dependency between cancer and normal cells in the last century (Warburg effect) (Vander Heiden, Cantley, & Thompson, 2009) . As a crucial hallmark of cancer, glycolysis is utilized by various oncogenic signalling pathways to promote cancer growth. The most common oncogenic pathway, PI3K/AKT, enhances glycolysis by up-regulating the glucose transporter GLUT1, while the Myc oncogene controls the transcription of several metabolic genes (Dang, 2012; Deberardinis, Lum, Hatzivassiliou, & Thompson, 2008) . Similarly, glycolytic enzymes are highly expressed in the biopsies of RA and SLE patients and are associated with their pathogenesis (Balakrishnan et al., 2014) . Consequently, various herbal agents have been investigated for the inhibition of glucose uptake and the glycolysis pathway, including inhibitors of GLUT1 (Quercetin) (Brito et al., 2016; Strobel et al., 2005) , hexokinase II (HKII) (methyl jasmonate) (Cesari et al., 2014) , pyruvate kinase M2 (PKM2) (shikonin) , α-enolase (ENO) (Rh2E2) and lactate dehydrogenase A (LDHA) (furanodiene and gossypol) (Le et al., 2010; Zhong et al., 2012) , which have shown desirable effects in preclinical studies. In particular, we found that the novel ginsenoside derivative Rh2E2 exhibits more potent suppression than aspirin in preventing the development of colorectal carcinoma and prohibiting lung cancer metastasis in mice. Additionally, the sub-chronic and acute toxicity LD 50 test for Rh2E2 showed no harmful reactions at the maximum oral dosage of 5000 mg/kg body weight in mice , indicating a promising perspective for Rh2E2 in the treatment of cancer via intervening with α-enolase to reduce the provision of ATP to cancer cells.
The TCA cycle generates the majority of ATP and intermediates that support cancer growth. The intermediates produced during the TCA cycle also promote cancer. For instance, oncogenic mutation of IDH has been found in multiple cancers and inflammatory diseases (Hartman et al., 2014) , resulting in catalytic reduction of α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2HG), which then accumulates (Dang et al., 2009) . Several IDH-targeted inhibitors have been developed thus far (Fujii et al., 2016) . Enasidenib by Agios has been approved by the FDA for clinical use. Some natural products have also been identified as effective inhibitors of mitochondria in vitro and in vivo, among which celastrol is a well-validated compound confirmed to directly target mitochondrial Complex I . In summary, the modulation of AMPK, glycolysis and mitochondrial metabolism with herbal chemicals through bioenergetic pathways shows encouraging results and is valuable for drug development for the treatment of cancer and autoimmune conditions.
Enhancing redox capacity to treat cancer and autoimmune conditions
The redox state represents the dynamic balance between oxidation and reduction. Many gaseous molecules have been well-documented with physiological, pathological and therapeutically functions, such as Nitric oxide (NO), Hydrogen sulfide (H 2 S) and various ROS etc. (Wu, Hu, & Zhu, 2016) , particularly the ROS control the redox signalling in cancer and inflammation. To maintain anti-oxidation capacity, NADPH acts as a key molecule that quenches the excessive ROS generated during increased proliferation and metabolism. As a byproduct of cell metabolism, ROS regulates both physiological and pathological conditions, acting as a double-edged sword. Some cancer and inflammatory cells depend on ROS to proliferate, but some cells die when ROS levels are elevated (Hultqvist, Olsson, Gelderman, & Holmdahl, 2009; Leung et al., 2016) . Therefore, the effectiveness of ROS elevation or elimination for treatment remains arguable and is probably dependent on the disease subtype and the individual involved (Cairns, Harris, & Mak, 2011; Chio & Tuveson, 2017) . Nevertheless, multiple therapeutic ROS elevators and ROS scavengers are available as treatment options for suitable individuals.
ROS elevators
To elevate ROS, two therapeutic strategies are available: consuming antioxidants to decrease NAPDH and inactivate reduction signalling pathways or using ROS inducers to increase ROS levels and activate oxidation signalling pathways. Because the major sources of endogenous ROS are mitochondria and NADPH oxidase (NOX), both are widely investigated as potential drug targets. Numerous lines of preclinical evidence have indicated that reducing mitochondrial ROS effectively inhibits cancerous and autoimmune cell proliferation in vitro and in vivo (Okamoto, 2008; Sullivan & Chandel, 2014) . Among the various ROS inducers available from natural products, the anti-malarial drug artemisinin is the best characterized, which acts by inducing ROS stress and DNA damage. Artemisinin could be directly converted to ROS, then intracellular Fe 2+ ions will cleave its endoperoxide linkages (R-O-O-R') and therefore generate toxic radicals (Ding et al., 2018; Kolemen et al., 2016) . Artemisinin administered i.p. shows an LD 50 of 1558 mg/kg (Gopalakrishnan & Kumar, 2015 ; "Studies on the toxicity of qinghaosu and its derivatives. China Cooperative Research Group on qinghaosu and its derivatives as antimalarials," 1982). Notably, recently discovered treatment strategies may provide new weapons to address the commonly observed problem of drug resistance in lung cancer patients. Sanguinarine, an alkaloid from the bloodroot plant, was first demonstrated as a potent NOX activator and consumes large amounts of cellular anti-oxidants with a low oral toxicity in rats (LD 50 1658 mg/kg) (Becci, Schwartz, Barnes, & Southard, 1987; Leung et al., 2016) . By activating NOX3, sanguinarine can selectively induce over-oxidation and degradation of a mutant epidermal growth factor receptor (EGFR T790M ) oncoprotein, while sparing normal EGFR, resulting in significant suppression of gefitinib-resistant lung tumours in vivo which was published in Antioxidants and Redox Signalling as cover story (Leung et al., 2016) . This novel strategy was subsequently reconfirmed and expanded for new nano-drug development by Peng et al., indicating the feasibility and therapeutic potential of this strategy for the treatment of drug-resistant lung cancer patients .
ROS scavengers
To suppress cancer cell growth via ROS stimulation, decreasing ROS elimination is an alternative method to activating enzymes responsible for ROS generation (Park et al., 2009 ). Humans exhibit anti-oxidation defence systems that protect against oxidation. For instance, nuclear factor erythroid 2-related factor 2 (Nrf2), the key transcription factor involved in the response to oxidative stress, significantly contributes to the suppression of Kras-driven carcinogenesis and autoimmune diseases (Romero et al., 2017; Wruck et al., 2011) . In patients with lung adenocarcinoma, approximately 20% of patients exhibit loss-of-function mutations in Kelch-like ECH-associated protein 1 (KEAP1), which is a negative regulator of Nrf2 (Romero et al., 2017) . Therefore, impairment of ROS scavenging renders transformed cells vulnerable to oxidative stress. A study using Nrf2 −/− knockout mice showed that licochalcone A (LCA), a compound derived from Glycyrrhizae radix, is effective in suppressing RA via Nrf2 activation (Su et al., 2018) . Sinomenine, a widely used herbal chemical marketed in China for the treatment of RA and inflammation, also exerts its immune-regulatory properties by regulating Nrf2 signalling (Qin et al., 2016; Zhou et al., 2017) , with a very low toxicity in mice (LD 50 of both oral and subcutaneous administration is N500 mg/kg) (Chang & But, 1986 ). S-progargyl-cysteine and calycosin are additional ROS scavengers identified from herbs that can activate Nrf2 (Su et al., 2016; . Among ROS scavengers, the thioredoxin (Trx)/thioredoxin reductase (TrxR) system serves as an important antioxidant enzyme scavenging ROS and repairing ROS-induced damage (Zhang, Li, Han, Liu, & Fang, 2017 ). Shikonin, a major active component of the Chinese medicinal herb 'ZiCao', is able to directly interact with the selenocysteine (Sec) residue in TrxR1 to inhibit its physiological function and collapse the intracellular redox balance (Duan, Zhang, Yao, Liu, & Fang, 2014; . Shikonin has been successfully used to treat multiple cancers and autoimmune diseases (Chen et al., 2003; Mao, Yu, Li, & Li, 2008) . The LD 50 of shikonin and its some derivatives in mice by i.p. administration ranged from 20 mg/kg to 48 mg/kg (Papageorgiou, Assimopoulou, Couladouros, Hepworth, & Nicolaou, 1999) . Additionally, parthenolide, a sesquiterpene lactone from Tanacetum parthenium, has been reported to target TrxR to induce apoptosis (Duan, Zhang, Yao, Liu, & Fang, 2016) .
Another potential anti-oxidation target is the sirtuins (SIRT), which are a family of NAD + -dependent deacetylases with multiple functions in cellular biology (Fried & Arbiser, 2009 ). Targeting SIRT3 using Honokiol, a small molecule polyphenol isolated from the Magnolia genus has been proven to be effective for cancer therapy Prasad, Kappes, & Katiyar, 2016) . The acute toxicity tests showed that the LD 50 of Honokiol was 50.5 mg/kg body weight in mice by i.v. injection . In addition to its anti-oxidation role, SIRT3 controls the expression of hypoxia-inducible factor 1 (HIF1), which directly regulates glycolytic enzyme expression in cancer cells and thus connects redox signalling to the glycolytic pathway. Thus, the imbalance of ROS in cancer and autoimmune diseases could be considered the Achilles's heel of cancer and autoimmune disease treatment.
Since the therapeutic potential of natural products in targeting cell metabolism and enhancing redox capacity for the treatment of cancerous and autoimmune diseases has been evidenced ( Fig. 1 and Table 1 ), there may be a solid foundation for the reasonable use of herbal medicines in combination with chemical drugs for treating complicated diseases in the future.
Modulating immunometabolism and redox capacity, mediated by the gut microbiome, to alleviate cancer and autoimmune conditions
Multiple studies have revealed the crucial role of microbiota symbiosis in causing or preventing various diseases, including cancer and autoimmune diseases, supported by rigorously controlled experiments using gnotobiotic mouse models colonized with one or more specific bacteria (Clemente, Ursell, Parfrey, & Knight, 2012; Karin, Lawrence, & Nizet, 2006) . The commensal microbiota influences metabolism, redox balance, inflammation and immunity not only locally at the gut mucosal level but also systemically (Clark & Mach, 2017; Nicholson et al., 2012) .
Herbal medicines show an interactive relationship with the gut microflora (Li, Zhou, Zhao, & Jia, 2009) ; the efficacy of some herbal medicines depends on directly modulating the microbiome or on indirect modulation through metabolites derived from bacteria (Sharon et al., 2014) . Collectively, the available evidence suggests that with the assistance of the gut microbiome, some herbal medicines are able to modulate cell metabolism and redox balance in gut epithelial cells and in other effector cells, ultimately exerting their anti-tumour or anti-inflammatory properties.
The role of gut microbial metabolites from herbal medicine
An increasing number of reports have described the bioactivity of polysaccharides, among which polysaccharides found in Chinese medicinal herbs are the best characterized and most clinically relevant (Ooi & Liu, 2000) , especially those from tonic herbs, such as Astragalus, Ganoderma lucidum polysaccharides, Lycium barbarum and Pachymaran polysaccharides. These polysaccharides have been reported to exhibit multiple biological functions, such as anti-tumour and anti-inflammatory activities and roles in the alleviation of gastrointestinal disorders (Nie, Lin, & Luo, 2017; Paiva et al., 2011; Yang et al., 2014) . The biological mechanisms underlying these effects require assistance from the gut microbiome; in particular, specific members of the gut microbiota, such as Akkermansia muciniphia, can metabolize polysaccharide molecules into short-chain fatty acids (SCFAs), including butyrate, propionate and acetate (Den Besten et al., 2013; Topping & Clifton, 2001), which ultimately affect local and systemic immune functions. Additionally, SCFAs activate G protein-coupled receptors (GPCRs) (Kimura et al., 2011; Koh, De Vadder, Kovatcheva-Datchary, & Backhed, 2016) , phospholipases A2 (PLA2) (Ohira, Tsutsui, & Fujioka, 2017) and phospholipase C (PLC) (Inoue et al., 2012) ; inhibit histone deacetylases (HDACs) (Waldecker, Kautenburger, Daumann, Busch, & Schrenk, 2008) ; stimulate histone acetyltransferase activity (Correa-Oliveira, Fachi, Vieira, Sato, & Vinolo, 2016); and stabilize HIF (Kelly et al., 2015) . Overexpression of HDACs is frequently observed in patients with cancer, which protects cancer cells from genotoxicity, while SCFAs can inactivate nonhistone proteins and induce ROS and DNA double-strand breaks, resulting in suppression of tumour growth (Rajendran, Ho, Williams, & Dashwood, 2011) . HIF modulates cellular oxygen homeostasis and metabolic activation and is heavily implicated in cancer biology (Semenza, 2003) , in addition to several other pathophysiological alterations, including autoimmune lupus (Deng et al., 2014) , arthritis , energy metabolism (Marin-Hernandez, GallardoPerez, Ralph, Rodriguez-Enriquez, & Moreno-Sanchez, 2009) and tumour invasion (Jing et al., 2012) . SCFAs such as butyrate can stabilize HIF to promote homeostasis in the distal intestine (Kelly et al., 2015) . Polysaccharide-K (PSK), a polysaccharide isolated from the cultured mycelium of the Basidiomycete Coriolus versicolor, suppressed tumours clinically and was approved for treatment of cancers of the digestive organs, lungs and breasts in 1976 (Maehara et al., 2012) . PSK could also additionally down-regulate the expression of HIF-1α under hypoxia in vivo in pancreatic cancer (Onishi, Morisaki, Nakao, Odate, & Katano, 2013) and colon cancer cells (Satoh et al., 2012) . Recently, SCFAs were reported to activate AMPK, which plays important roles in both T cells (Ma, Poffenberger, Wong, & Jones, 2017) and cancer cell metabolism (Den Besten et al., 2013; Shackelford & Shaw, 2009) , causing pronounced inhibition of the growth of non-small-cell lung carcinoma cells, lymphoma cells and hepatocellular carcinoma cells (Way, Tsai, Wang, Ho, & Chou, 2014) .
In addition, SCFAs promote the release of ROS and nitric oxide (NO), which are involved in neutrophil phagocytosis of bacteria (Vinolo et al., 2011; Vinolo, Hatanaka, Lambertucci, Newsholme, & Curi, 2009 ), indicating that SCFAs could modulate redox capacity. Previous reports revealed that polysaccharides from Tussilago farfara leaves and Acorus calamus rhizomes can stimulate NO synthase (NOS) in murine macrophages on a level comparable to that of lipopolysaccharides (Danilets et al., 2010) , while Ganoderma lucidum polysaccharides relieve oxidative stress by increasing the levels of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in serum and gastric tissues of rats with gastric cancer (Pan, Jiang, Liu, Miao, & Zhong, 2013) . Astragalus polysaccharides prevent the progression of type 1 diabetes mellitus (DM) by correcting the redox status via inducing nitric oxide synthase (iNOS) down-regulation and SOD up-regulation (Chen, Li, & Yu, 2008) . Hence, it is increasingly thought that SCFAs function as the major effective metabolites of herbal polysaccharides; however, it remains unclear whether the beneficial effects of herbal polysaccharides are driven by single SCFAs, such as butyrate or whether they act in combination with other metabolites. Thus, additional intensive investigations are needed to elucidate the exact roles and precise mechanisms of these herbal polysaccharide metabolites in the treatment of cancer and autoimmune diseases.
In addition to polysaccharides, the gut microbiota metabolize individual herbal chemicals that enhance cell metabolism and the redox capacity in gut epithelial cells and influence immune effector cells to treat cancer and autoimmune conditions. For instance, baicalin can be converted into an active enteric microbiome metabolite known as baicalein, which induces autophagic cell death through activating AMPK/ULK1 and down-regulating mTORC1 complex components, resulting in suppression of cancer (Aryal et al., 2014) .
Notably, modulation of microbiota shows promise as a new strategy for future antineoplastic and anti-arthritis treatments. Just recently, we found that oral administration of a single bacteria Lactobacillus casei (L. casei) could significantly ameliorate adjuvant-induced arthritis of rats (AIA). It has been well-known that L. casei, as a beneficial bacteria in the gut, can enhance the production of SCFAs (Leblanc et al., 2017) , rebuild the balance of oxidative stresses (Maragkoudakis, Chingwaru, Gradisnik, Tsakalidou, & Cencic, 2010) and modulate mucosal immune cells (Hardy, Harris, Lyon, Beal, & Foey, 2013) in intestinal epithelium, contributing to its anti-arthritic effects. We compared the alterations of microbiotas in probiotics, Chinese herb medicine GuanJieKang (GJK) and MTX treated AIA rats based on the gene catalog of rat gut microbiome (Pan et al., 2018) . Interestingly, GJK, which is composed of Astragali Rzdix (10 g), Glycyrrhizae Radix (6 g), Paeniae Radix Alba (12 g), Aconiti Laterdis Radix Praparata (10 g) and Corydalis Rhizoma (10 g), acts similar restoration on microbiotas to L. casei and methotrexate (MTX), indicating that GJK and MTX relieve arthritis via similar modulation on gut microbiota. Thus, modulation of gut microbes by herbal chemicals could be potentially developed into new preventive and therapeutic strategies for arthritis partly through their effects on cell metabolism and ROS (Fig. 2) . Potentiating the accumulation of p62 and the degradation of KEAP1, thereby inducing Nrf2 nuclear translocation (Qin et al., 2016; Su et al., 2016; Su et al., 2018; Wu, Jia, et al., 2016 ) Sinomenine, S-progargyl-cysteine Inducing KEAP1 degradation
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The role of gut microbiome-dependent ROS production
Previous reports showed that specific gut microbiota control the response of cancer to therapy by modulating the tumour microenvironment and ROS production (Iida et al., 2013; Roy & Trinchieri, 2017) . Diverse commensal bacteria show distinct capacities for inducing cellular ROS generation, exhibiting powerful induction of ROS production by lactobacilli; however, the majority of bacteria assayed exhibit some degree of ability to induce ROS generation in host epithelial cells (Jones & Neish, 2017) . Additionally, lactobacilli harbour membrane components or secreted factors that trigger cellular responses. For example, the soluble factors produced by Lactobacillus rhamnosus GG could mediate beneficial effects in in vivo injury animal models (Yan et al., 2007) . In addition, lactobacilli that stimulate ROS might present an enhanced ability to penetrate the mucus layer or show the ability to enhance adhesive properties to contact cellular receptors, such as formyl peptide receptors (FPRs).
Several Chinese medicinal herbs may act as prebiotics in the host due to their beneficial effect on the induction of cellular ROS by expanding probiotics such as Lactobacillus. Sulforaphene (LFS-01) is a natural compound derived from a traditional medicinal plant; oral administration of LFS-01 dramatically alters the skewed gut microbiota and reverses colitis in mice in association with increases in intestinal γδT cells . Through 16S rDNA sequencing, LFS-01 was shown to selectively suppress enteric pathogens such as Escherichia-Shigella and Helicobacter, whereas protective strains, including Lactobacillus and Lachnospiraceae, were significantly expanded after LFS-01 treatment . Oral administration of diosgenin markedly restores the reduced density of faecal lactic acid bacteria (LAB) (Huang, Cheng, Deng, Chou, & Jan, 2012) . Through induction of ROS by modulating the gut microbiome, these compounds could be used as a component of a cocktail remedy, in combination with chemotherapy or immunotherapy.
Several studies have indicated that bile acids (BAs) rapidly induce ROS and reactive nitrogen species collectively. Using intestine-specific farnesoid X receptor (FXR) knockout (FXR int−/− ) mice, researchers found that BBR prevented the development of high-fat-diet-induced obesity and ameliorated triglyceride accumulation in the liver of wildtype mice, but not in FXR int−/− mice, indicating that BBR may exert its lipid-lowering effect primarily in the gut, by modulating the turnover of bile acids. Additionally, there was an increase in primary BAs and a decrease in secondary BAs in BBR-treated animals, associated with significant production of cellular ROS . These results imply that the effects of herbs on the alteration of ROS might be related to their effects on bile acid. Overall, the gut microbiota plays an essential role in metabolizing herbal medicine to exert its effect on cell metabolism and redox modulation, and further investigation of this topic is required ( Fig. 3 and Table 2 ).
Integrating multiple advanced technologies to study the effects of herbal chemicals on cell metabolism and redox modulation
Although increasing evidence supports the development of new strategies for modulating metabolic and redox capacity using effective Fig. 2 . New strategy for suppressing arthritis via modulating gut microbiome. Adjuvant induced arthritis (AIA) in rats were significantly improved by Lactobacillus casei (L. casei), Chinese herbal formula (GJK) and methotrexate (MTX). L. casei redirected dysbiosis in the microbiome of arthritic rats towards normal, as well as inhibiting pro-inflammatory cytokines and bone destruction. Interestingly, GJK and MTX shared most of the restored microbiotas similar to that by L. casei. The alterations in gut microbial compositions contributed to the changes in serum metabolites (like short chain fatty acids (SCFAs)), redox capacity and mucosal immune cells, which finally resulted in suppressing aberrant immune responses and amelioration of AIA. Abbreviations: AIA: Adjuvant induced arthritis; FXR: formyl peptide receptor; GJK: GuanJieKang; IL-17: interleukin-17; IL-6: interleukin-6; IL-1β: interleukin-1β; IFN-γ: interferon-γ; L. casei: Lactobacillus casei; MTX: methotrexate; Nrf2: Nuclear factor (erythroid-derived 2) -like 2; Nox1: NADPH oxidase 1; ROS: reactive oxygen species; SCFAs: short chain fatty acids; TNF-α: tumor necrosis factor-α.
herbal chemicals derived from medicinal plants to treat cancer and autoimmune conditions, multiple challenges remain. For instance, it is unclear which single herbal chemicals or combinational remedies are the most effective and present the most potential and should therefore be further intensively investigated. Such research will be focussed on the development of clinical therapeutics, the metabolic and redox targets of these chemicals are the precise mechanisms underlying the therapeutic outcomes of their modulation of cell metabolism and redox capacity. With increases in advanced technologies, it is important to elucidate the mechanisms of disease pathogenesis as well as drug actions. Cancer and autoimmune diseases are regarded as genetic and epigenetic disorders involving multiple forms of cross-talk among pathological signalling pathways and molecules (Giat, Ehrenfeld, & Shoenfeld, 2017; Hemminki, Liu, Ji, Sundquist, & Sundquist, 2012) . Consequently, effective therapies for these diseases must involve multi-target approaches. Hence, advanced technologies are required to demonstrate how the metabolic network and the redox capacity efficiently impact these multiple correlated genetic and epigenetic factors. Fig. 3 . Schematic programme of holistic metabolic and redox modulation with multiple herbal chemicals mediated by the gut microflora. Abbreviations: AMPK, AMP-activated protein kinase; BA, Bile acid; CAT, Catalase; FPR, Formyl peptide receptor; GI tract, Gastrointestinal tract; GSH-Px, Glutathione peroxidase; HDAC, Histone deacetylase; HIF-1α, Hypoxia inducible factor-1α; iNOS, Inducible nitric oxide synthase; KEAP1, Kelch-like ECH-associated protein 1; NO, Nitric oxide; NOX1, NADPH oxidase 1; Nrf2, Nuclear factor (erythroidderived 2)-like 2; Maf, Minor allele frequency; mTORC1, Mammalian target of rapamycin; PLA2: Phospholipases A2; PLC, Phospholipase C; PRG, Protein-coupled receptor; ROS, Reactive oxygen species; SCFAs, Short-chain fatty acids.
Table 2
Effects of functional components derived from herbal medicine on crosstalk among the gut microbiome, immunometabolism and redox capacity. Li, Fan, et al., 2017) Diosgenin
Rhizoma Dioscoreae Nipponicae
Restoring the diminished density of faecal lactic acid bacteria (Huang et al., 2012) Berberine
Coptis chinensis
Increasing primary BAs and decreasing secondary BAs Abbreviation: AMPK, AMP-activated protein kinase; BA, Bile acid; CAT, Catalase; GSH-Px, Glutathione peroxidase; HIF-1α, Hypoxia inducible factor-1α; iNOS, Inducible nitric oxide synthase; NO, Nitric oxide; mTORC1, Mammalian target of rapamycin; SOD, Superoxide dismutase.
Furthermore, the identification of potential molecular targets and biomarkers associated with the pathogenesis, pathology, diagnosis and treatment of diseases will not only accelerate research in the field of medical sciences but also benefit millions of patients suffering from cancer and autoimmune diseases (Table 3) .
Multi-omics and computational technologies used for drug discovery of herbal medicine
The discovery of new small molecules from herbal medicine showing ideal treatment efficacy for cancer and autoimmune diseases, but still remains a challenge scientifically. However, the multiple available omics technologies have expanded our view regarding the identification of new diagnostic biomarkers and drug action targets. For instance, mutation of the critical TCA cycle enzyme IDH1 has been widely accepted as a metabolic biomarker and therapeutic target in gliomas, which was first identified in a genome-wide analysis using next-generation sequencing (NGS) technology (Parsons et al., 2008) . Enasidenib, a potent inhibitor targeting the mutated IDH protein, developed by Agios Pharmaceuticals Inc., has been approved by the FDA, and is being evaluated in multiple clinical studies. Single molecule real-time (SMRT) third-generation sequencing subsequently emerged as a powerful tool for long-read sequencing (Roberts, Carneiro, & Schatz, 2013) , which dramatically enhances our ability to fully explore new pathogenic biomarkers and targets associated with diseases, leading to strides in precision medicine.
In addition to genomic profiling, metabolic profiling can generate rich data on metabolic alterations, reflecting genetic, epigenetic, and environmental factors related to systemic diseases (Priolo et al., 2014) . Currently, Wang et al. of our laboratory group developed an innovative glycomic platform based on a specialized ultrasensitive microfluidic chip for in-depth glycomic analysis of human serum IgGs to identify new acidic N-glycosylation-associated biomarkers in RA patients; this platform provides insightful analysis for personalized antibody or target-drug design, in addition to achieving, early, precise diagnosis of RA . Zhai et al. identified the serum ratio of branchedchain amino acids to histidine as a novel osteoarthritis biomarker, showing the clinical potential of metabolomics, by applying electrospray ionization tandem MS technology for targeted metabolite profiling of knee osteoarthritis patients (Zhai et al., 2010) . Additionally, the advancement of genome-scale metabolism modelling (GSMM) by integrating cognitive computing and genomic sequencing has boosted new drug discovery by combining information on new metabolism gene mutations with in silico drug screening based on molecular docking (Yizhak, Chaneton, Gottlieb, & Ruppin, 2015) .
In past decades, combinational remedies involving multi-target agents have shown specific capabilities in treating complicated diseases, leading to the development of better medical care strategies in clinical trials (Sharma & Allison, 2015) . In fact, the principles of combinational therapy are treated as a cornerstone in TCM (Li & Weng, 2017) . Unfortunately, the impetus to apply such principles in Western medicine has only recently been increasing, related to the treatment of several Table 3 Advanced technologies for drug discovery and elucidation of the targets of action and mechanisms of medicinal plants.
Technology Description
Perspective application Reference
Herbal drug discovery TiO 2 -PGC chip
A microfluidic chip combining a TiO 2 column for acidic N-glycans enrichment with a PGC column chromatographically, for N-glycans separation
Enabling accurate quantification of extremely low-abundance N-glycans on IgGs ) Identifying N-glycosylation-associated biomarkers GSMM An approach integrating cognitive computational mathematics and modelling with genomic sequencing
Capturing metabolic effects at the network-wide level (Yizhak et al., 2015) Discovering drug biomarkers associated with metabolism SMRT sequencing A highly accurate method with a long-read next-generation sequencing technology Improving eukaryotic genome and bacterial genome assemblies substantially as well as epigenetic phenomena (Roberts et al., 2013) Discovering potential pathogenic biomarkers AI Computational reformulation of herbal formulas Personalizing drug combinations with efficient optimization (Leung et al., 2013; Schneider, 2017) Motivating the advancement of herbal medicine formulas in clinical therapy Quantitative structure activity relationship modelling Identify molecules which can directly regulate the target activity (Zhang, Sun, Yan, & Wang, 2017) Elucidation of intervention mechanism Q-TOF-MS A dominant high-resolution MS platform with a Q-TOF spectrometer Providing a faster spectral acquisition rate, combined with powerful separation techniques for tracking metabolites (Zhang, Li, et al., 2015) Disclosing the intervention mechanisms of herbal medicines CyTOF A mass cytometer combining traditional flow cytometry with coupled plasma-mass spectrometry diseases (Anaya et al., 2016; X Deng & Nakamura, 2017; Koenders & van den Berg, 2015) . Hence, combinational therapy will serve as a powerful basis for drug discovery by exploiting the synergistic advantages derived from multiple effective components in Chinese medicinal herbs and other natural sources. One promising current advancement in the field of computational and pharmaceutical sciences is the application of artificial intelligence (AI) to reformulate herbal formulas, with computationally efficient optimization of the dosage of each active component from herbs, to build the best synergy of drug actions; this strategy is being evaluated in our laboratories (Leung et al., 2013) and by other organizations (Schneider, 2017) .
Furthermore, AI and computational tools are widely applied to guide drug screening. By calculating the 3D structure of compounds and target and evaluating the target activity, such as pharmacodynamics property, biochemical changes and therapeutic effect, AI-aided drug design and discovery approach are potential a breakthrough in drug discovery. Identifying the efficient drugs from chemical libraries by AI model, such as quantitative structure activity relationship (QSAR) modelling, was demonstrated to be cost-effective method which largely reduces the cost and time for pharmaceutical industry to acquire candidate drugs from massive amounts of data (Zhang, Tan, Han, & Zhu, 2017) . Especially in current big data era, how to quickly and cheaply discover active molecules from massive amount of candidate chemicals is a major issue. Computer-aided approach provides a guide for it. By collaborating informatics with medicinal chemistry, machine intelligence can catapult us into the future (Molloy, 2018; Zhang, Bo, et al., 2015) .
Mass spectrometry and image technologies used for elucidating mechanisms of herbal medicine
Significant advancements are emerging in the use of mass spectrometry (MS) for the identification of endogenous metabolites associated with drug actions; in particular, MS is being widely used to understand the therapeutic mechanisms of herbal medicines in various diseases (Zhang, Sun, et al., 2017; Zhang, Sun, & Wang, 2016) . Quadrupole time-of-flight MS (Q-TOF-MS) has been utilized as a powerful tool for metabolomics studies to elucidate the therapeutic mechanisms of herbal medicines (Zhang, Li, et al., 2015) . Current advanced mass cytometry by time-of-flight (CyTOF) technology exhibits a strong capacity to reveal drug pharmacokinetics, including simultaneous quantitative and qualitative deep metabolic profiling of immune cells at the singlecell level (Atkuri, Stevens, & Neubert, 2015; Bendall et al., 2011) . Recently, Passarelli et al. developed a state-of-the-art 3D OrbiSIMS instrument combining the proven high mass-resolution power of an Orbitrap for high-spatial-resolution 3D imaging platform secondary ion MS (SIMS) with the highest-speed TOF spectrometer available (Passarelli et al., 2017) . The 3D OrbiSIMS enables metabolic imaging and captures hundreds of compounds in a single measurement with a subcellular resolution. These vital tools will broaden our understanding of where a drug is located in our body, even to the single-cell level, as well as how the drug impacts the complex responses resulting from on-target and off-target engagement with the treated diseases.
Nuclear magnetic resonance (NMR) is another powerful and appropriate analytic technique for investigating how aberrant metabolic transformation rewires energy production and biosynthetic processes in cells (Tavares, Jarak, Nogueira, Oliveira, & Carvalho, 2015) . Positional enrichment by proton analysis (PEPA), a novel metabolomics approach based on NMR, significantly broadens the coverage of metabolic profiling, with higher sensitivity, and goes beyond classical assessment of labelled metabolites via NMR (Vinaixa et al., 2017) . Positional isotopomer NMR tracer analysis (PINTA) provides a non-invasive method for assessing the role of alterations of hepatic mitochondrial and glucose metabolism in various pathophysiologic states in humans (Perry et al., 2017) , which greatly improves the examination of drug-target engagement for therapeutic intervention. Positron emission tomography (PET) combined with X-ray computed tomography (CT) produces images providing molecular information and anatomic localization in tumours. PET-CT devices have been established as an important clinically applied diagnostic tool based on the original idea of dysregulated glucose metabolism in cancer cells, which attracts more radioactive-labelled glucose (Heusner et al., 2008; Lee et al., 2014) . Subsequently, magnetic resonance (MR) imaging integrated with PET (Lee, Catalano, & Dehdashti, 2015; Schaarschmidt et al., 2015) was developed to obtain more comprehensive information on glucose metabolism in cancer patients; PET imaging has additionally been used to measure the dynamics of various tumour metabolic processes in vivo and to provide insight into drug-target engagement or alterations (Clark, Ebiana, Gosa, Cloughesy, & Nathanson, 2017) . Thus, increased utilization of advanced technologies will accelerate the discovery of additional herbal metabolic and redox drugs for the pharmaceutical industry and will facilitate diverse clinical applications in the future.
Conclusion and perspectives
The principle or philosophy of modern medicine should arrive at a new era in this century. Genotype-and cell-based treatment strategies have dominated in past decades but show limitations in the treatment of cancer and autoimmune diseases because body parts do not function as separate units but is interconnected. The efficiency of using only a mono-target "anti-disease treatment strategy" should be extensively re-evaluated. Might we instead switch to a new holistic combinatory and modulatory approach for the treatment or monitoring complex disease? With increasing research evidence, it appears that therapeutic agents should be comprehensively designed to manipulate the optimal levels or ratios of catabolism/anabolism and oxidation/reduction to achieve better treatment outcomes. No single agent can exhibit such synergy, and a combination of drugs is needed to normalize cell metabolism and the ROS state, similar to traditional herbal formulas, which are often prepared with several different herbs, according to the disease status and individual condition of the patient. Currently, precision diagnosis of complicated diseases using advanced technologies and modulation of metabolism and the redox state using multiple active components isolated from herbs appear to be promising for serving the increasing demands of holistic medical care for complex diseases, further promoting the development of precision medicine (Fig. 4) .
Considering the application of herbal medicine in ancient countries, existing commonly used herbs have been shown to exhibit treatment efficacy and low toxicity. In perspective, the increasing reports of artificial organ technologies, such as the development of artificial livers, may inspire additional valid drug screening and evaluation methods. Hopefully, we may be able to screen and evaluate a drug combination in multiple artificial organs in the future, to elucidate the drug treatment effect at the system level for the body, which will enhance the success rate of new drug development by the pharmaceutical industry. Further basic and translational research, drug development and clinical trials should be conducted to discover useful herbal agents and better understand their treatment benefits and mechanisms. In addition, further validation using clinical samples is needed to validate the reported metabolic targets and biomarkers and to define which subgroup of patents will receive the treatment benefits of personalized medicine. Overall, using a holistic approach to modulate metabolism and redox state is promising for treatment of systemic diseases. We believe that advanced technologies can accelerate innovative herbal drug discovery and guide clinical practice using additional metabolic and redox biomarkers and diagnosis tools in a rational, specific, personalized, non-invasive and controllable manner.
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